Skip to main content

Verrica Pharmaceuticals Inc.

corporate_fare Company Profile

Verrica Pharmaceuticals Inc.

VRCA·NASDAQ·Life Sciences·CIK 0001660334

The company is a therapeutics company that develops and commercializes medications for dermatologic diseases, including skin cancers. Its current commercial product and pipeline candidates are clinician-administered therapies. The product portfolio includes one approved product for molluscum contagiosum, or molluscum, with potential for additional indications, and other pipeline candidates. Its commercial product, YCANTH (VP-102), received U.S. Food and Drug Administration (FDA) approval in July 2023 for treating molluscum in adult and pediatric patients two years of age and older. YCANTH (VP-102) is a proprietary drug-device combination containing a GMP-controlled formulation of cantharidin. The company is developing YCANTH (VP-102) for a potential follow-on indication for common warts. Its second development candidate, VP-315 (ruxotemitide), is an oncolytic peptide-based injectable therapy for dermatology oncologic conditions, including basal cell carcinoma (BCC). The company is focusing its efforts and financial resources on the commercialization of YCANTH (VP-102) for molluscum, the development of YCANTH (VP-102) for common warts, and the development of VP-315 for BCC. YCANTH (VP-102) (cantharidin) 0.7% topical solution was the first FDA-approved product for molluscum on July 21, 2023. The company commercially launched YCANTH (VP-102) in August 2023 in the United States. As of December 31, 2025, it has a specialized sales organization of approximately 40 field employee sales representatives in the United States, targeting pediatric dermatologists, dermatologists, pediatricians, and select other primary care healthcare providers. Molluscum is a contagious skin disease caused by a pox virus, typically presenting with 10 to 30 lesions, and sometimes over 100 lesions.

Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 17 items for VRCA at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-13, rated 8/10. Across its 17 most recent items scored 7 or higher, the top rating is 9/10, with 10 rated 8 or above. Recent SEC coverage for VRCA spans 10-Q, 8-K, 4, DEF 14A.

Recent high-impact activity:

  • Verrica 10-Q: Record YCANTH Revenue, but Going-Concern Warning as Cash Falls to $14.4M
  • Verrica Q3 Revenue Up 58% to $5.7M; Runway Extended Into Q4 2027
  • YCANTH Revenue Jumps 57.9% to $5.7M as Verrica Secures $27.5M Growth Capital
  • Verrica Completes Enrollment in Pivotal COVE-2 Warts Trial; Topline Data Due Q1 2027
  • CEO Jayson Rieger Buys $125,750 of Verrica Stock in Open Market

Financial Snapshot

Fiscal year ended December 31, 2025
Revenue
$35.58M
Net Income
-$17.89M
Diluted EPS
-$1.68
Op. Cash Flow
-$17.63M
Free Cash Flow
-$17.63M
Operating Income
-$12.19M
Cash & Equivalents
$30.15M
Total Debt
$0
Debt / Equity
0.00×
Net Margin
-50.3%
Shares Outstanding
17.18M sh
Source: 10-K · filed 2026-03-11 · accession 0001660334-26-000008

Short Interest & Short Volume

4.58 days to cover

FINRA reported short interest of 244,405 shares in VRCA as of the October 30, 2026 settlement, a 26.9% increase from the prior period — about 4.6 days to cover at its recent average daily volume. On November 20, 2026, 38.2% of VRCA volume reported to FINRA trade-reporting facilities was marked short.

Short interest (bi-monthly positions)244,405 shares as of October 30, 2026
Change vs prior period▲ 26.9%
Days to cover4.58 at avg daily volume of 53,391
Daily short volume (FINRA facilities)38.2% of 60,323 shares on November 20, 2026
5-day average short volume36.3%

Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.

Browse all tickers starting with V →
$2.85 -1.21% today
52-week range · as of 2026-11-13 $2.85 – $9.82
Market cap
$47.07M
Volume
127K (2.0× avg)
3-mo avg 64.4K
Live data · 2026-11-21 19:15 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed VRCA - Latest Insights

VRCA
Nov 13, 2026, 7:53 AM EST
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $3.87
Real-time Price: $2.85 info
Change: -$1.02 (-26%) info
Market Cap: $47.07M info
VRCA
Nov 12, 2026, 4:27 PM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $3.71
Real-time Price: $2.85 info
Change: -$0.860 (-23%) info
Market Cap: $47.07M info
VRCA
Nov 12, 2026, 4:16 PM EST
Source: Wiseek News
Importance Score:
7
Price at Filing: $3.71
Real-time Price: $2.85 info
Change: -$0.860 (-23%) info
Market Cap: $47.07M info
VRCA
Aug 27, 2026, 8:00 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $4.76
Real-time Price: $2.85 info
Change: -$1.91 (-40%) info
Market Cap: $47.07M info
VRCA
Aug 18, 2026, 5:00 PM EDT
Filing Type: 4
Importance Score:
7
Price at Filing: $4.68
Real-time Price: $2.85 info
Change: -$1.83 (-39%) info
Market Cap: $47.07M info
VRCA
Aug 06, 2026, 4:37 PM EDT
Filing Type: 10-Q
Importance Score:
9
Price at Filing: $5.36
Real-time Price: $2.85 info
Change: -$2.51 (-47%) info
Market Cap: $47.07M info
VRCA
Aug 06, 2026, 4:34 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $5.36
Real-time Price: $2.85 info
Change: -$2.51 (-47%) info
Market Cap: $47.07M info
VRCA
Jul 21, 2026, 8:00 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $5.80
Real-time Price: $2.85 info
Change: -$2.95 (-51%) info
Market Cap: $47.07M info
VRCA
Jun 22, 2026, 8:05 AM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $5.63
Real-time Price: $2.85 info
Change: -$2.78 (-49%) info
Market Cap: $47.07M info
VRCA
Jun 09, 2026, 4:05 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $6.12
Real-time Price: $2.85 info
Change: -$3.27 (-53%) info
Market Cap: $47.07M info
VRCA
May 12, 2026, 4:15 PM EDT
Filing Type: 10-Q
Importance Score:
9
Price at Filing: $7.15
Real-time Price: $2.85 info
Change: -$4.30 (-60%) info
Market Cap: $47.07M info
VRCA
May 12, 2026, 4:12 PM EDT
Source: Reuters
Importance Score:
7
Price at Filing: $7.15
Real-time Price: $2.85 info
Change: -$4.30 (-60%) info
Market Cap: $47.07M info
VRCA
May 12, 2026, 4:07 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $7.15
Real-time Price: $2.85 info
Change: -$4.30 (-60%) info
Market Cap: $47.07M info
VRCA
May 08, 2026, 5:21 PM EDT
Source: Reuters
Importance Score:
7
Price at Filing: $7.99
Real-time Price: $2.85 info
Change: -$5.14 (-64%) info
Market Cap: $47.07M info
VRCA
Apr 20, 2026, 4:10 PM EDT
Filing Type: DEF 14A
Importance Score:
8
Price at Filing: $6.38
Real-time Price: $2.85 info
Change: -$3.53 (-55%) info
Market Cap: $47.07M info
VRCA
Mar 11, 2026, 8:11 AM EDT
Filing Type: 10-K
Importance Score:
8
Price at Filing: $6.21
Real-time Price: $2.85 info
Change: -$3.36 (-54%) info
Market Cap: $47.07M info
VRCA
Mar 11, 2026, 8:10 AM EDT
Source: Reuters
Importance Score:
8
Price at Filing: $5.25
Real-time Price: $2.85 info
Change: -$2.40 (-46%) info
Market Cap: $47.07M info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets